mCRPC Clinical Trials in New York, New York
8 recruitingNew York, New York
Showing 1–8 of 8 trials
Recruiting
Phase 2
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Prostate Cancer Clinical Trials Consortium126 enrolled5 locationsNCT06844383
Recruiting
Phase 1Phase 2
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Arsenal Biosciences, Inc.190 enrolled9 locationsNCT07285694
Recruiting
Phase 1
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Brain Metastases)
Duke Street Bio Ltd180 enrolled15 locationsNCT06458712
Recruiting
Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Solid Tumor+7 more
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 1Phase 2
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Prostate CancerMetastatic Castration-resistant Prostate CancerUrogenital Neoplasms+3 more
Blue Earth Therapeutics Ltd82 enrolled21 locationsNCT05413850
Recruiting
Phase 1
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Castration-resistant Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)+2 more
K36 Therapeutics, Inc.144 enrolled13 locationsNCT07103018
Recruiting
Phase 2
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals20 enrolled9 locationsNCT06004661
Recruiting
Phase 1Phase 2
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Metastatic Castration-resistant Prostate Cancer (mCRPC)Clear-Cell Renal-Cell Carcinoma (ccRCC)
Regeneron Pharmaceuticals345 enrolled21 locationsNCT03972657